News
AIM
0.2490
-0.40%
-0.0010
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
NASDAQ · 2d ago
Bet on 5 Top-Ranked Stocks With Rising P/E
NASDAQ · 3d ago
Weekly Report: what happened at AIM last week (0713-0717)?
Weekly Report · 6d ago
AIM ImmunoTech Stockholders Approve Key Equity Proposals
TipRanks · 07/17 09:18
Weekly Report: what happened at AIM last week (0706-0710)?
Weekly Report · 07/13 09:53
Weekly Report: what happened at AIM last week (0629-0703)?
Weekly Report · 07/06 09:55
Weekly Report: what happened at AIM last week (0622-0626)?
Weekly Report · 06/29 09:52
AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026
Benzinga · 06/24 12:31
Weekly Report: what happened at AIM last week (0615-0619)?
Weekly Report · 06/22 09:58
AIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027
NASDAQ · 06/22 09:44
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
Barchart · 06/22 07:45
AIM ImmunoTech Regains NYSE Compliance With Increased Stockholders' Equity
NASDAQ · 06/16 09:03
AIM ImmunoTech Regains NYSE American Listing Compliance
TipRanks · 06/15 12:36
Weekly Report: what happened at AIM last week (0608-0612)?
Weekly Report · 06/15 09:59
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 06/12 17:05
AIM ImmunoTech Raises Capital via Registered Direct Offering
TipRanks · 06/11 21:49
AIM ImmunoTech Updates Bylaws on Shareholder Voting Standards
TipRanks · 06/10 22:15
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 06/09 17:06
AIM ImmunoTech announces $2.65M financing priced at-market
Seeking Alpha · 06/09 13:54
AIM ImmunoTech Inc trading resumes
TipRanks · 06/09 13:50
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.